Generic Name: risperidone
Brand Name: Perseris
Manufacturer: HLS Therapeutics Inc.
Therapeutic Area: Schizophrenia, adults
Indications: Treatment of schizophrenia in adults.
Manufacturer Requested Reimbursement Criteria1: Treatment of schizophrenia in adults.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule C
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||December 24, 2020|
|Call for patient/clinician input closed||February 22, 2021|
- Patient input submission received from Institute for Advancements in Mental Health
|Submission received||January 29, 2021|
|Submission accepted||February 12, 2021|
|Review initiated||February 23, 2021|
|Draft CADTH review report(s) provided to sponsor for comment||May 07, 2021|
|Deadline for sponsors comments||May 18, 2021|
|CADTH responses on draft review report(s) provided to sponsor||July 09, 2021|
|Expert committee meeting (initial)||July 21, 2021|
|Draft recommendation issued to sponsor||August 03, 2021|
August 05, 2021